Inmune Bio, Inc. (INMB)
Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. NV
What they're doing
Between 2026-06-21 and 2026-09-19, public records show 2 signals for Inmune Bio, Inc.. Most notable: 2026-09-14: Filed 8-K disclosing director or officer change; 2026-07-01: Filed 8-K disclosing material agreement. Federal contract obligations over the last 24 months total $0. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.
Generated 2026-09-19 from public records.
Signals, last 12 months
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing director or officer change
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2024-09-30 | Moss David J | officer | P | 10,000 | 5.29 | $52,900 |
| 2024-09-12 | Tesi Raymond Joseph | director | P | 15,380 | 6.38 | $98,124 |
| 2024-09-12 | Moss David J | officer | P | 7,690 | 6.38 | $49,062 |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
No Wikipedia pageview data linked to this company.